144 related articles for article (PubMed ID: 28787954)
1. Evaluation of Lapatinib Powder-Entrapped Biodegradable Polymeric Microstructures Fabricated by X-Ray Lithography for a Targeted and Sustained Drug Delivery System.
Jeong EG; Yoo HJ; Song B; Kim HP; Han SW; Kim TY; Cho DD
Materials (Basel); 2015 Feb; 8(2):519-534. PubMed ID: 28787954
[TBL] [Abstract][Full Text] [Related]
2. Carrageenan: A Wonder Polymer from Marine Algae for Potential Drug Delivery Applications.
Qureshi D; Nayak SK; Maji S; Kim D; Banerjee I; Pal K
Curr Pharm Des; 2019; 25(11):1172-1186. PubMed ID: 31465278
[TBL] [Abstract][Full Text] [Related]
3. Assessing the viability of Soluplus® self-assembled nanocolloids for sustained delivery of highly hydrophobic lapatinib (anticancer agent): Optimisation and in-vitro characterisation.
Bonde GV; Ajmal G; Yadav SK; Mittal P; Singh J; Bakde BV; Mishra B
Colloids Surf B Biointerfaces; 2020 Jan; 185():110611. PubMed ID: 31704609
[TBL] [Abstract][Full Text] [Related]
4. Incorporation of lapatinib into human serum albumin nanoparticles with enhanced anti-tumor effects in HER2-positive breast cancer.
Wan X; Zheng X; Pang X; Zhang Z; Zhang Q
Colloids Surf B Biointerfaces; 2015 Dec; 136():817-27. PubMed ID: 26539808
[TBL] [Abstract][Full Text] [Related]
5. Azo polymeric micelles designed for colon-targeted dimethyl fumarate delivery for colon cancer therapy.
Ma ZG; Ma R; Xiao XL; Zhang YH; Zhang XZ; Hu N; Gao JL; Zheng YF; Dong DL; Sun ZJ
Acta Biomater; 2016 Oct; 44():323-31. PubMed ID: 27544813
[TBL] [Abstract][Full Text] [Related]
6. Chk1 activation attenuates sensitivity of lapatinib in HER2-positive gastric cancer.
Bai M; Song N; Che X; Wang X; Qu X; Liu Y
Cell Biol Int; 2018 Jul; 42(7):781-793. PubMed ID: 29271513
[TBL] [Abstract][Full Text] [Related]
7. HSP90 inhibitor, AUY922, debilitates intrinsic and acquired lapatinib-resistant HER2-positive gastric cancer cells.
Park KS; Hong YS; Choi J; Yoon S; Kang J; Kim D; Lee KP; Im HS; Lee CH; Seo S; Kim SW; Lee DH; Park SR
BMB Rep; 2018 Dec; 51(12):660-665. PubMed ID: 30591093
[TBL] [Abstract][Full Text] [Related]
8. Hydroxyapatite/poly(epsilon-caprolactone) composite coatings on hydroxyapatite porous bone scaffold for drug delivery.
Kim HW; Knowles JC; Kim HE
Biomaterials; 2004; 25(7-8):1279-87. PubMed ID: 14643602
[TBL] [Abstract][Full Text] [Related]
9. Investigation of Polycaprolactone Matrices for Intravaginal Delivery of Doxycycline.
Pathak M; Coombes AGA; Turner MS; Palmer C; Wang D; Steadman KJ
J Pharm Sci; 2015 Dec; 104(12):4217-4222. PubMed ID: 26398713
[TBL] [Abstract][Full Text] [Related]
10. Biodistribution of biodegradable polymeric nano-carriers loaded with busulphan and designed for multimodal imaging.
Asem H; Zhao Y; Ye F; Barrefelt Å; Abedi-Valugerdi M; El-Sayed R; El-Serafi I; Abu-Salah KM; Hamm J; Muhammed M; Hassan M
J Nanobiotechnology; 2016 Dec; 14(1):82. PubMed ID: 27993139
[TBL] [Abstract][Full Text] [Related]
11. Fabrication of doxycycline-loaded electrospun PCL/PEO membranes for a potential drug delivery system.
Eskitoros-Togay ŞM; Bulbul YE; Tort S; Demirtaş Korkmaz F; Acartürk F; Dilsiz N
Int J Pharm; 2019 Jun; 565():83-94. PubMed ID: 31063838
[TBL] [Abstract][Full Text] [Related]
12. Perspective highlights on biodegradable polymeric nanosystems for targeted therapy of solid tumors.
Fathi M; Barar J
Bioimpacts; 2017; 7(1):49-57. PubMed ID: 28546953
[No Abstract] [Full Text] [Related]
13. The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines.
Kim JW; Kim HP; Im SA; Kang S; Hur HS; Yoon YK; Oh DY; Kim JH; Lee DS; Kim TY; Bang YJ
Cancer Lett; 2008 Dec; 272(2):296-306. PubMed ID: 18774637
[TBL] [Abstract][Full Text] [Related]
14. Biodegradable polymers for targeted delivery of anti-cancer drugs.
Doppalapudi S; Jain A; Domb AJ; Khan W
Expert Opin Drug Deliv; 2016 Jun; 13(6):891-909. PubMed ID: 26983898
[TBL] [Abstract][Full Text] [Related]
15. Stimuli-responsive chitosan-based nanocarriers for cancer therapy.
Fathi M; Sahandi Zangabad P; Majidi S; Barar J; Erfan-Niya H; Omidi Y
Bioimpacts; 2017; 7(4):269-277. PubMed ID: 29435435
[No Abstract] [Full Text] [Related]
16. Functional genetic approach identifies MET, HER3, IGF1R, INSR pathways as determinants of lapatinib unresponsiveness in HER2-positive gastric cancer.
Zhang Z; Wang J; Ji D; Wang C; Liu R; Wu Z; Liu L; Zhu D; Chang J; Geng R; Xiong L; Fang Q; Li J
Clin Cancer Res; 2014 Sep; 20(17):4559-73. PubMed ID: 24973425
[TBL] [Abstract][Full Text] [Related]
17. Biodegradable Microsphere-Hydrogel Ocular Drug Delivery System for Controlled and Extended Release of Bioactive Aflibercept In Vitro.
Liu W; Lee BS; Mieler WF; Kang-Mieler JJ
Curr Eye Res; 2019 Mar; 44(3):264-274. PubMed ID: 30295090
[TBL] [Abstract][Full Text] [Related]
18. [Proceedings of new drug delivery systems and their applications in the traditional Chinese drugs].
Zhou SH; Xiao XH; Yuan HL; Zhao YL; Shan LM; Cai GM
Zhongguo Zhong Yao Za Zhi; 2003 Jul; 28(7):589-92. PubMed ID: 15139097
[TBL] [Abstract][Full Text] [Related]
19. Polymer based microspheres of aceclofenac as sustained release parenterals for prolonged anti-inflammatory effect.
Kaur M; Sharma S; Sinha VR
Mater Sci Eng C Mater Biol Appl; 2017 Mar; 72():492-500. PubMed ID: 28024613
[TBL] [Abstract][Full Text] [Related]
20. Development of a sustained-release biodegradable polymer delivery system for site-specific delivery of oligonucleotides: characterization of P(LA-GA) copolymer microspheres in vitro.
Lewis KJ; Irwin WJ; Akhtar S
J Drug Target; 1998; 5(4):291-302. PubMed ID: 9713978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
